Svizera Labs Private Limited

Svizera Labs Private Limited, established on April 17, 1997, is a private pharmaceutical company headquartered in Thane, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U74999MH1997PTC107389. It operates as a non-government entity, classified as a private company limited by shares. The authorized share capital is ₹5.00 crore, with a paid-up capital of ₹2.80 crore. As of the latest available data, the company employs approximately 60 professionals. Svizera Labs specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's registered office is located at Plot No D-16/6, TTC-MIDC Industrial Area, Turbhe, Thane, Maharashtra, 400703.

Svizera Labs operates manufacturing facilities in the TTC-MIDC Industrial Area, Turbhe, Thane, Maharashtra. The plant specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Specific details regarding production capacities and certifications are not publicly disclosed. The company's focus on quality manufacturing aligns with its export activities, particularly in the tuberculosis medications segment.

The leadership team at Svizera Labs Private Limited comprises:

• Maneesh Ramakant Sapte – Director, appointed on November 13, 2000.
• Vinay Ramakant Sapte – Director, appointed on April 1, 2002.
• Rashmi Vinay Sapte – Director, appointed on April 9, 1999.
• Pareshkumar Pravinchandra Upadhyay – Director, appointed on November 28, 2019.

These individuals collectively oversee the strategic direction and operations of the company.

Svizera Labs Private Limited's export activities are primarily focused on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's export data indicates a total export value of $13.7 million USD across 273 shipments, with a portfolio concentration of 100% in its top five products. The top five products exported are Rifampicin ($3.9M), Isoniazid ($3.8M), Ethambutol ($2.3M), Pyrazinamide ($1.9M), and Strip ($1.8M). These products are primarily categorized under tuberculosis medications (59.0%), advanced antibiotics (28.2%), and medical devices & diagnostics (12.8%). The company's export data does not specify its presence in regulated markets such as the US, EU, UK, Australia, or Japan. Without detailed regulatory filings, approvals, or market access status, a comprehensive analysis of Svizera Labs' presence in these markets cannot be provided.

Svizera Labs Private Limited's export data indicates a significant focus on tuberculosis medications, which are critical in emerging markets, particularly in regions with high TB prevalence. The company's export portfolio includes Rifampicin, Isoniazid, Ethambutol, and Pyrazinamide, all essential components in TB treatment regimens. While the export data does not specify the exact destinations of these products, the emphasis on TB medications suggests potential penetration into emerging markets in Africa, Latin America, and Southeast Asia. The World Health Organization (WHO) prequalification of these products would facilitate access to these markets, ensuring compliance with international quality standards. However, without specific information on WHO prequalification status, a detailed assessment cannot be provided.

Svizera Labs Private Limited's export data reveals a concentrated portfolio, with its top five products accounting for 100% of its export value. This indicates a high level of concentration risk, as the company's revenue is heavily dependent on a limited number of products. The therapeutic focus on tuberculosis medications and advanced antibiotics suggests a strategic direction aimed at addressing global health challenges. However, the lack of diversification in product offerings may expose the company to market fluctuations and regulatory changes affecting these specific product categories. A more diversified product portfolio could mitigate such risks and enhance the company's resilience in the global pharmaceutical market.

The export data provided does not include specific information regarding Svizera Labs Private Limited's interactions with the U.S. Food and Drug Administration (FDA). Without details on FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection history, a comprehensive assessment of the company's FDA status cannot be conducted. The absence of this information limits the ability to evaluate the company's compliance with FDA regulations and its potential market access in the United States.

The export data does not provide information on Svizera Labs Private Limited's compliance with World Health Organization (WHO) Good Manufacturing Practices (GMP) or European Union (EU) GMP standards. Without details on WHO prequalification or EU GMP certificates, it is challenging to assess the company's adherence to these international quality standards. Compliance with WHO and EU GMP is crucial for market access in various regions and for ensuring the safety and efficacy of pharmaceutical products.

Svizera Labs Private Limited's export data does not include specific information regarding its compliance with the Central Drugs Standard Control Organisation (CDSCO) regulations or approvals from state drug controllers in India. Without details on CDSCO manufacturing licenses, state drug controller approvals, or export No Objection Certificates (NOCs), a comprehensive assessment of the company's adherence to Indian regulatory standards cannot be conducted. Compliance with CDSCO regulations is essential for the legal manufacturing and export of pharmaceutical products in India.

The available data does not indicate any recent regulatory actions involving Svizera Labs Private Limited, such as Form 483 observations, warning letters, or import alerts. The absence of such information suggests that the company has not faced significant regulatory challenges in recent times. However, without access to detailed regulatory records, a comprehensive evaluation cannot be performed.

Svizera Labs Private Limited operates in the pharmaceutical export sector, focusing on finished formulations for tuberculosis and advanced antibiotics. The company's top five products—Rifampicin, Isoniazid, Ethambutol, Pyrazinamide, and Strip—are essential components in TB treatment regimens. The competitive landscape in this segment includes other pharmaceutical companies that manufacture and export similar products. However, without specific market share data and information on key competitors, a detailed head-to-head analysis cannot be conducted. The company's emphasis on high-quality manufacturing and a focused product portfolio may provide a competitive edge in addressing global health challenges related to tuberculosis.

Svizera Labs Private Limited's key differentiators include its specialized focus on tuberculosis medications and advanced antibiotics, which are critical in global health initiatives. The company's export data indicates a significant presence in these therapeutic areas, suggesting expertise and a commitment to addressing pressing health concerns. Additionally, the company's emphasis on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, aligns with global trends towards ready-to-use dosage forms. However, the lack of diversification in its product portfolio may limit its ability to cater to a broader range of therapeutic areas.

Svizera Labs Private Limited's current strategic direction appears to be focused on the export of finished pharmaceutical formulations, particularly in the areas of tuberculosis medications and advanced antibiotics. This focus aligns with global health priorities and addresses critical needs in the treatment of infectious diseases. The company's concentrated product portfolio suggests a strategy aimed at leveraging expertise in specific therapeutic areas. However, the lack of diversification may expose the company to risks associated with market fluctuations and regulatory changes affecting these specific product categories. Future strategic initiatives could include expanding the product portfolio to include other therapeutic areas, thereby enhancing resilience and market reach.

Svizera Labs Private Limited's export data indicates a total export value of $13.7 million USD across 273 shipments, with a portfolio concentration of 100% in its top five products. This suggests a consistent and focused approach to its export activities. The company's emphasis on high-quality manufacturing aligns with its export focus on critical medications for tuberculosis and advanced antibiotics. However, the lack of diversification in its product offerings may expose the company to risks associated with market fluctuations and regulatory changes affecting these specific product categories. A more diversified product portfolio could mitigate such risks and enhance the company's resilience in the global pharmaceutical market.

Importers should verify the following certifications to ensure compliance with international quality standards:

• FDA Approval: Confirm that the products are approved by the U.S. Food and Drug Administration